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Aim To identify gross deletions in the NF2 gene in a panel 
of schwannomas from Croatian patients in order to estab-
lish their frequencies in Croatian population.
Methods Changes of the NF2 gene were tested by poly-
merase chain reaction/loss of heterozygosity (LOH) using 
two microsatellite markers, D22S444 and D22S929.
Results The analysis with both markers demonstrated that 
43.75% of schwannomas exhibited LOH of the NF2 gene. 
The D22S444 region exhibited 45.5% of LOHs and the 
D22S929 region exhibited 14.3% of LOHs. Four LOHs were 
found in Antoni B, 2 in Antoni A, and 1 in Antoni A and B 
type tumors.
Conclusion The frequency of changes observed in Cro-
atian patients is broadly similar to that reported in other 
populations and thus confirms the existing hypothesis re-
garding the tumorigenesis of schwannomas and contrib-
utes to schwannoma genetic profile helping us to better 
understand its etiology and treatment.
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Schwannomas are benign encapsulated tumors of Schwann 
cells, the main peripheral glia cells that do not invade the 
nerve, but rather grow around it. It is extremely rare for a 
schwannoma to transform and become malignant (1,2). 
The majority of schwannomas arise spontaneously and 
only 4% are associated with neurofibromatosis type 2 (NF2). 
Sporadic schwannomas represent 6%-8% of all intracranial 
tumors. Additionally, schwannomas make up to 90% of tu-
mors that occur in the cerebellopontine angle (3). During 
the last decade, great progress has been made in the deter-
mination of molecular and genetic characteristics causative 
of both sporadic and familial forms of schwannomas.
Schwannomas are a principal feature of two hereditary tu-
mor diseases, NF2 and schwannomatosis. NF2 is an auto-
somal dominant disorder caused by germline mutations in 
the NF2 gene on 22q12. The population-based birth inci-
dence of NF2 was estimated as 1 case in 33 000-40 000 indi-
viduals (4,5). Approximately 50% of NF2 cases harbor muta-
tions de novo, which cannot be identified in any other family 
members, and this suggests a high mutation rate for this 
gene (1,3). The hallmark of this disorder is the clinical finding 
of bilateral schwannomas involving the eighth cranial nerve 
(vestibular schwannomas) (6,7). Schwannomas also occur 
spontaneously, ie, sporadically. An annual incidence of spo-
radic vestibular schwannoma was approximately 1.3 per 
100 000 (8). A population-based study in Denmark showed 
an estimated incidence of 11.5 cases per million inhabitants 
per year (9), while the US national tumor registry reported 
1.1 cases per 100 000 people per year. Loss of heterozygos-
ity, ie, gross deletion of the NF2 gene is a common feature 
found in the majority of sporadic schwannomas. At present, 
it seems that all sporadic schwannomas are caused by some 
kind of alteration of NF2 gene (10). The majority of detected 
deletions and mutations result in a truncated (shorter) pro-
tein products (11). The evidence very strongly suggests that 
all schwannomas are caused by changes in both gene cop-
ies and the consequent loss of NF2 protein function (12).
The main reason why we propose studying NF2 gene in 
schwannomas is because there are still many unsolved 
and inadequately explained issues regarding the full ge-
netic profile of human schwannomas. Today, it is recog-
nized that alterations of the NF2 gene are a causative event 
in the tumorigenesis of schwannomas. Therefore, identifi-
cation of gross deletions of NF2 gene in a set of patients 
from Croatia (the first time on a southeastern European 
population) can contribute to our knowledge of the total 
frequency of NF2 alterations and thus improve our un-
derstanding of this tumor’s etiology.
MaTeRIals aND MeTHoDs
Tumor specimen
Samples of 20 schwannomas, together with autologous 
blood samples, were collected from the Department of 
Neurosurgery and Department of Pathology, Sestre Milosrd-
nice University Hospital, Zagreb, Croatia. The patients were 
without clinical NF1, NF2, or Schwannomatosis and had 
no family history of brain tumors. The schwannoma tissues 
were frozen in liquid nitrogen and transported to the labo-
ratory, where they were immediately transferred at -75°C. 
The peripheral blood samples were collected in ethylenedi-
aminetetraacetic acid (EDTA) and processed immediately.
Magnetic resonance imaging (MRI) revealed that the ma-
jority of schwannomas were intracranial, while two were 
located in the spinal nerves. During the operative proce-
dure, the schwannomas were removed using a microneu-
rosurgical technique. They were studied and classified ac-
cording to WHO criteria by pathologists. Our study was 
approved by the ethics committees of Medical School Uni-
versity of Zagreb and Sestre Milosrdnice University Hospi-
tal, and the patients gave their informed consent.
DNa extraction
Approximately 0.5 g of tumor tissue was homogenized 
with 1 mL extraction buffer (10 mM Tris HCl, pH 8.0; 0.1 M 
EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) and incubated 
with proteinase K (100 μg/mL; Sigma, St. Louis, MO, USA; 
overnight at 37°C). Phenol chloroform extraction and etha-
nol precipitation followed.
Blood was used to extract leukocyte DNA. Five milliliters of 
blood was lysed with 7 mL distilled water and centrifuged 
(15-minute/5000 g). The pellet was processed as for DNA 
extraction from the tissue samples.
Polymerase chain reaction
Two polymorphic regions, D22S444 and D22S929, of the 
NF2 gene were studied. In a total volume of 25 μL, two 
polymorphic markers were amplified by using 5 pmol of 
each primer (Table 1), 200 ng DNA, 2.5 μL 10X buffer II (500 
mM KCl, 100 mM Tris-HCl, pH 8.3), 1.5 mM MgCl
2, 2.5 mM 
of each dNTP, 0.2 μL (1U) of Taq polymerase (Promega, 
Madison, WI, USA). PCR conditions: initial denaturation, 10 
minutes/95°C; denaturation, 30 seconds/95°C; annealing, 
30 seconds/55°C; extension, 30 seconds/72°C; final exten-
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sion, 72°C/10 minutes; 35 cycles. All PCR products were an-
alyzed on 2% agarose gels.
loss of heterozygosity
To assess LOH of the NF2 gene, markers D22S444 (13,14) 
and D22S929 (15,16) were chosen from the literature and 
professional gene databases (EntrezGene http://www.
ncbi.nlm.nih.gov/). Heterozygous samples were visualized 
on Spreadex EL 400 gels (Elchrom Scientific, Cham, Swit-
zerland), stained with SyberGold (Molecular Probes, Le-
iden, The Netherlands) and on 15% polyacrylamide gels, 
stained with silver. Absence or a significant decrease in the 
intensity of one of the D22S444 and D22S929 alleles in tu-
mor, as compared with the autologous blood sample, was 
considered as LOH of NF2 gene.
ResulTs
Schwannomas were classified as WHO grade I and speci-
fied as Antoni A or Antoni B (17) patterns (Figure 1 A and 
B). Seven (35%) were Antoni A, 9 (45%) were Antoni B, and 
4 (20%) had mixed Antoni A and Antoni B features.
Our data set consisted of 20 patients, 15 female. The age of 
the patients ranged from 12 to 67 years (mean age 50.95; 
median 52.50). The mean age at diagnosis was 33 years for 
men and 57 years for women. Their symptoms lasted be-
tween 2 to 72 months (mean 38.95; median 42.0).
The localization of the tumor was as follows: 11 were left 
vestibular (50%) (Figure 2), 6 were right vestibular (25%), 
one was found in the right temporal region (IX nerve), 
while two were found in the left spinal LI and LII nerves. 
Intracranial schwannomas were predominantly found in 
women.
Of 20 schwannoma samples, 16 were informative when 
analyzed with both NF2 gene markers (80%). Eleven 
(55%) were informative for D22S444 and 14 (70%) for 
D22S929 microsatellite marker. The results regarding NF2 
gene showed 7 out of 16 heterozygous patients with al-
lelic losses (43.75%). This is the total number of changes 
analyzed by both microsatellite markers. When specifying 
changes to distinct gene regions, there were 5 LOHs dis-
covered with D22S444 (45.5%) and 2 LOHs discovered with 
D22S929 (14.3%). The LOHs were lost for one marker and 
not the other. D22S929 is an intragenic marker in intron 
1 of the NF2 gene, so our results showed that in patients 
heterozygous for D22S929 with loss of the distal marker 
D22S444 the deletion would start somewhere down-
stream of the first exons.
LOHs of the NF2 gene, revealed by both markers, are shown 
in Figure 3A (D22S444) and B (D22S929).
TaBle 1. Primers used for the amplification of microsatellite 
markers for the NF2 gene





FIguRe 1. Vestibular schwannoma, (A) antoni a. Tumors were composed of compact spindle cells that had twisted nuclei and indis-
tinct cytoplasmic borders. They were arranged in short bundles. Nuclear palisading and Verocay bodies were present. (B) antoni B. 
The tumor was composed of loosely arranged schwann cells admixed with foamy macrophages. In some tumor cells degenerative 
nuclear changes were seen but mitotic activity was not observed (200 × , hematoxylin and eosin).
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When assigning the gross deletions of the NF2 gene to a 
specific pathohistological classification, the distribution of 
LOHs was as follows: 4 LOHs were found in Antoni B tumors 
(57%), 2 in Antoni A (29%), and 1 in Antoni A and B tumors 
(14%). The pathohistologic diagnosis of the analyzed sam-
ples, along with the LOH of the NF2 gene and polymorphic 
status of both microsatellite markers is shown in Table 2.
DIscussIoN
Our analysis using two microsatellite markers found 43.75% 
samples with gross deletions of the NF2 gene. We have al-
ready mentioned that gross deletions of the NF2 gene are 
frequent events in the molecular pathology of sporadic 
schwannoma (11). Although it is well known that the main 
cause for transformation of the Schwann cells into schwan-
nomas is the inactivation of the NF2 gene, and the consec-
utive loss of its protein merlin, the intracellular mechanism 
of this transformation still needs to be elucidated. It seems 
that the inactivation of the second allele often occurs via a 
large deletion of the 22q chromosomal region.
The investigated marker D22S929 is an intragenic mark-
er located within the 32.2-kb-long intron 1 of the NF2 
gene (15,16). It is a dinucleotide repeat (15) with report-
ed heterozygosity of 83%, while our sample showed the 
heterozygosity of 70%. The genetic alterations were found 
in the NF2’s intron, indicating intragenetic target of this 
deletion. The marker D22S444 is a tetranucleotide repeat 
proximal to the NF2 gene, with reported informativity of 
79% (18). The rates of allelic loss were different between 
the markers used. This variability of LOHs found in those 
TaBle 2. The analyzed samples, loss of heterozygosity of the NF2 gene, and polymorphic status of D22s444 and D22s929 markers
Patient No. localization antoni D22s444 D22s929 symptoms/months sex age
1 VIII* left B Heterozygous Heterozygous 72 F 64
2 Spinal LII left A Homozygous Homozygous  3 M 40
3 VIII right B LOH Homozygous 42 F 50
4 VIII left A Homozygous Homozygous  5 F 53
5 VIII right B Homozygous Homozygous 36 F 62
6 VIII left B Heterozygous LOH 24 F 33
7 VIII left B LOH Heterozygous 54 F 51
8 VIII left A Homozygous LOH 66 M 26
9 VIII right A LOH Homozygous 42 M 12
10 VIII right B Homozygous Heterozygous 36 F 63
11 IX right A Homozygous Homozygous 36 F 59
12 VIII left A + B Homozygous Heterozygous 30 F 52
13 VIII left B LOH Heterozygous 60 F 67
14 VIII right B Homozygous Heterozygous 54 F 51
15 VIII left B Heterozygous Heterozygous 66 F 67
16 VIII left A+B Heterozygous Heterozygous 48 F 67
17 Spinal LI left A Heterozygous Heterozygous  2 F 49
18 VIII left A+B LOH Heterozygous 48 M 60
19 VIII left A Heterozygous Heterozygous 48 M 27
20 VIII right A+B Homozygous Heterozygous  7 F 66
*VIII = eighth cranial nerve in the cerebellopontine angle (vestibular cranial schwannoma).
FIguRe 2. Magnetic resonance image showing lesion in the 
left pontocerebellar angle.
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two genetic regions could indicate more precisely the po-
sition of the deleted part and the size this deletion encom-
passes in our cases. The variability of the results obtained 
by different microsatellite markers can also elucidate the 
involvement of genomic instability regarding DNA replica-
tion and postreplication repair.
This type of analysis has never previously been performed 
on a cohort of patients from Croatia, and we believe that 
our results could broaden the overall NF2 mutational spec-
trum. Our results are in accordance with the frequency of 
LOHs in sporadic schwannomas reported by other authors 
(19,20). In other studies, the frequency of LOHs in schwan-
nomas was from 40%-80% – a fairly large range – which 
depended on the number of genetic markers used and the 
number of cases examined (19-26). An incidence of 42.6% 
of LOHs assessed by 4 microsatellite markers, a number 
that is very similar to our result, was reported in the study 
by Bian et al (19). Moreover, the same study reported differ-
ence in NF2 LOHs between vestibular and spinal schwan-
nomas and the association of higher proliferative index to 
the schwannomas showing LOH. Hadfield et al (20) report-
ed LOH occurrence in 54 out of 96 (56%) sporadic vestibu-
lar schwannomas, a frequency that while clearly higher is 
not significant (χ2 = 0.433). There are reports of even higher 
frequencies of losses (22), which detected 72% of NF2 de-
letions by direct sequencing and 77% of LOHs (23). Ves-
tibular schwannomas were also analyzed by comparative 
genomic hybridization in several studies. Loss on 22q was 
reported in 23% of sporadic schwannomas (24), in which 
case it was slightly more common in tumors associated to 
NF2 than those found in sporadic cases, but this difference 
was not significant. Moreover, Warren et al (25) examined 
66 sporadic vestibular schwannomas and found 23.7% of 
losses; while Koutsimpelas et al (26) found losses on the 
chromosome 22 in 30% of the cases. Mantripragada et al 
(21) performed a high resolution study using an array cov-
ering 1/3 of human chromosome 22 and found LOH in 
45% of schwannomas. An important feature common to 
all of these analyses is the relatively small number of cases. 
As systematized in a meta-analysis of 12 years of studying 
of the mutational spectrum of NF2 gene (8), it is obvious 
that the overall number of investigated sporadic cases re-
mains rather small. Our sample therefore represents ap-
proximately 8% of the total worldwide sample size, and is 
the first that is derived from southeastern Europe.
Loss of expression of NF2 protein product merlin is a uni-
versal finding in all schwannomas examined, indicating in-
activation of both NF2 alleles. The loss of immunoreactivity 
was reported in many studies (23,24,27). The main char-
acteristic of cells lacking NF2 protein product is the loss 
of contact inhibition of proliferation (28). Associated with 
the loss of contact inhibition, merlin-lacking cells are also 
known to contain defective adherens junctions (29). Thus, 
it is understandable that cells that suffered merlin loss 
show deregulated adhesion to extracellular matrix, which 
is also shown in schwannoma cells. Furthermore, merlin 
seems to be directly involved in cytoskeletal organiza-
tion relevant to myelination (30). Recent research on NF2 
gene has demonstrated that merlin is a tumor suppres-
sor capable of modulating a wide range of signaling 
FIguRe 3. losses of heterozigosity (loHs) of the NF2 gene in schwannomas. (A) lanes 1, 3, 6 – samples demonstrating loH at 
D22s444; lanes 2, 4, 5 –corresponding blood samples; lanes 7, 8 – uninformative patient. (B) lane 1 –100 bp DNa standard; lanes 
5, 7, 11 –samples demonstrating loH at D22s929; lanes 4, 6, 10 – corresponding blood samples; lanes 2, 3 – heterozygous patient 
without loH; lanes 8, 9 – uninformative patient.
BASIC SCIENCE326 Croat Med J. 2012;53:321-7
www.cmj.hr
pathways that influence cell growth, motility, and apopto-
sis (30). It is clear that merlin is involved in different signal 
transduction pathways, Hippo and Ras/Raf/Mek pathways 
being the best characterized, while the latest reports also 
suggest merlin’s connection to the wnt signaling pathway 
(31,32). It has been shown that merlin’s inactivation is in-
volved in about half of sporadic meningiomas, too. In our 
previous investigation on meningiomas, two LOHs of the 
NF2 gene were found with the D22S929 marker (33).
When assigning the gross deletions of the NF2 gene to a 
specific pathohistological classification, in our study the 
distribution of LOHs was not associated to any particular 
morphology. As schwannomas are benign tumors that 
respond poorly to classical chemotherapeutics and of-
ten result in morbidity, the current therapies of choice are 
surgery and radiosurgery, but it is equally important to de-
velop novel therapeutic approaches. In this context, un-
derstanding how merlin’s loss causes tumorigenesis would 
in all likelihood open the door for new therapies. As intrac-
ranial schwannomas are relatively rare, our sample repre-
sents a valuable asset to the analysis of NF2 gross deletions 
in intracranial sporadic cases.
In conclusion, the frequency of NF2 allelic losses observed 
in Croatian patients is broadly similar to that reported in 
other populations and thus both confirms the existing hy-
pothesis regarding the tumorigenesis of schwannomas, 
and contributes to schwannoma genetic profile, helping 
us to better understand its etiology and treatment.
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